DOI,title,author,year,times_seen
10.1001/jama.2016.0287,The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),Singer,2016,1
10.1186/s13054-019-2378-9,Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR),Guilhaumou,2019,2
10.1345/aph.1g467,Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli,Lorente,2006,1
10.1177/0091270003257225,Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem,Kuti,2003,1
10.1016/s0732-8893(02)00390-5,Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997–2000),Jones,2002,1
10.1128/aac.42.7.1762,"Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)",Pfaller,2018,1
10.1016/0196-6553(91)90157-8,National nosocomial infections surveillance system (NNIS): Description of surveillance methods,Emori,2005,1
10.1017/s0195941700066091,Will the Real Infection Rate Please Stand?,Fuchs,2016,1
10.1017/s0195941700066108,The Impact of Postdischarge Infection on Surgical Wound Infection Rates,Reimer,2016,1
10.1093/oxfordjournals.aje.a113990,THE EFFICACY OF INFECTION SURVEILLANCE AND CONTROL PROGRAMS IN PREVENTING NOSOCOMIAL INFECTIONS IN US HOSPITALS,HALEY,2017,1
10.1046/j.1198-743x.2001.00295.x,Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters,Jacobs,2003,1
10.1016/s0732-8893(96)00135-6,"Results of the Alexander Project: A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens",Grüneberg,2002,2
10.1128/aac.34.11.2075,"Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States",Jorgensen,2012,1
10.1007/s40262-017-0602-9,Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children,Béranger,2017,2
10.1007/s40262-018-0682-1,Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance,Béranger,2018,1
10.1093/cid/cis857,Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis,Falagas,2012,1
10.1128/aac.47.11.3442-3447.2003,"Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study",Zanetti,2003,1
10.1093/jac/28.4.569,A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia,Edelstein,2007,1
10.1016/s1473-3099(19)30403-7,"Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial",Kollef,2019,2
10.1007/s10096-019-03535-w,Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis,Hartman,2019,1
10.1016/j.ejps.2021.105868,Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis,Li,2021,1
10.1016/j.xphs.2021.02.001,Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling,Zhou,2021,1
10.1016/j.xphs.2020.06.010,A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment,Ye,2020,1
10.1002/jps.24373,Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds,Zhang,2015,1
10.1177/0091270009333209,Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches,Hosea,2009,1
10.1124/jpet.105.094052,Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H<sub>2</sub>Receptor Antagonists,Tahara,2006,1
10.1146/annurev.pharmtox.44.101802.121856,Transporters and Renal Drug Elimination,Lee,2004,1
10.1016/s0300-483x(02)00296-2,Transporters and xenobiotic disposition,Kim,2002,1
10.1074/jbc.273.16.10046,The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver,Gerloff,2002,1
10.1097/01.ccm.0000194725.48928.3a,Sepsis in European intensive care units: Results of the SOAP study*,Vincent,2006,1
10.1001/jama.1995.03530120060042,"Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults",Brun-Buisson,2011,1
10.1086/320186,"Characterization of<i>Pseudomonas aeruginosa</i>Isolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999",Gales,2002,1
10.1093/jac/42.2.128,Extended-spectrum beta-lactamases in Pseudomonas aeruginosa,Nordmann,2002,1
10.1097/inf.0b013e3182a743c7,Population Pharmacokinetics of Piperacillin/Tazobactam in Critically Ill Young Children,Cies,2013,2
10.1378/chest.11-1671,Subtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients,Udy,2011,1
10.1086/514622,The Pharmacodynamics of β‐Lactams,Turnidge,2007,1
10.1093/clinids/6.supplement_4.s870,Failure of a Once-Daily Regimen of Cefonicid for Treatment of Endocarditis Due to Staphylococcus aureus,Chambers,2011,1
10.1186/cc11862,A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia,Kollef,2012,1
10.1002/phar.2505,A guide to therapeutic drug monitoring of β‐lactam antibiotics,Fratoni,2021,1
10.1093/cid/cis856,"Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial",Dulhunty,2012,1
10.1056/nejm200103083441001,Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis,Bernard,2002,1
10.1111/resp.13115,The respiratory threat posed by multidrug resistant Gram-negative bacteria,Rodrigo-Troyano,2017,1
10.1016/s0140-6736(14)61136-3,The role of the microbiome in exacerbations of chronic lung diseases,Dickson,2014,1
10.1034/j.1399-3003.1999.13b21.x,Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease,Zalacain,2003,1
10.1097/pcc.0000000000001497,Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus,Cies,2018,1
10.1345/aph.1r216,Continuous and Extended Infusions of β-Lactam Antibiotics in the Pediatric Population,Walker,2012,1
10.1097/mcc.0b013e3282e2a98f,Continuous infusion of beta-lactams,Mouton,2007,1
10.1016/s0149-2918(04)90051-3,Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis*1,KUTI,2004,1
10.5863/1551-6776-22.4.276,Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children,Cies,2017,1
10.1002/phar.1476,Pharmacokinetics of Continuous-Infusion Meropenem in a Pediatric Patient Receiving Extracorporeal Life Support,Cies,2014,1
10.1093/cid/ciu027,DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?,Roberts,2014,2
10.1001/jama.2009.1754,International Study of the Prevalence and Outcomes of Infection in Intensive Care Units,Vincent,2009,1
10.1093/jac/dkaa468,Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study,Wu,2020,1
10.1093/tropej/fmu017,Monotherapy with Amikacin or Piperacillin-Tazobactum Empirically in Neonates at Risk for Early-Onset Sepsis: A Randomized Controlled Trial,Tewari,2014,1
10.1002/jcph.566,Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia,Xiao,2015,1
10.1128/aac.32.12.1845,Disposition of ceftazidime in surgical patients with intra-abdominal infection,Heim-Duthoy,2012,1
10.1097/cce.0000000000000446,Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?,Barreto,2021,1
10.1007/s00134-017-4878-x,"Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach",Bassetti,2017,1
10.1111/j.1749-4486.2009.01973.x,A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant<i>Pseudomonas aeruginosa</i>; a preliminary report of efficacy,Wright,2009,1
10.1099/00222615-37-4-258,Treatment of experimental infections of mice with bacteriophages,SOOTHILL,2009,1
10.1128/cmr.3.4.293,Branhamella catarrhalis: an organism gaining respect as a pathogen,Catlin,2016,1
10.3389/fphar.2019.01191,Antibiotic Treatment of Suspected and Confirmed Neonatal Sepsis Within 28 Days of Birth: A Retrospective Analysis,Wagstaff,2019,1
10.1016/s0140-6736(17)31002-4,Neonatal sepsis,Shane,2017,1
10.1016/s0140-6736(09)60071-4,"Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial",Carr,2009,1
10.1002/14651858.cd000361.pub2,Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants,Ohlsson,2004,1
10.1093/clinids/12.supplement_4.s392,Immunotherapy and Immunoprophylaxis in the Newborn Infant: The Need for Definitive Clinical Trials,Johnston,2011,1
10.1093/cid/cis545,Does the Piperacillin Minimum Inhibitory Concentration for Pseudomonas aeruginosa Influence Clinical Outcomes of Children With Pseudomonal Bacteremia?,Tamma,2012,1
10.1016/j.ijantimicag.2007.06.015,Pseudomonas aeruginosa bloodstream infections: how should we treat them?,van Delden,2007,1
10.1002/phar.1567,"Pharmacokinetics of Continuous-Infusion Meropenem for the Treatment of <i>Serratia marcescens</i>
 Ventriculitis in a Pediatric Patient",Cies,2015,1
10.1093/jac/dkx093,Dose optimization of piperacillin/tazobactam in critically ill children,De Cock,2017,1
10.1007/s00467-008-0997-5,Human renal function maturation: a quantitative description using weight and postmenstrual age,Rhodin,2008,1
10.1016/s0272-6386(00)70341-6,Mouse to elephant: Biological scaling and Kt/v,Singer,2008,1
